This site is intended for healthcare professionals

The next global epidemic

Read time: 5 mins
Last updated:2nd Sep 2020
Published:21th Aug 2020
Despite damaging the liver, most people with NASH are not aware that they have a liver problem. In this series of articles, we share the epidemiology and current management strategies of NASH as well as the potential for new drug therapies.

As the levels of obesity around the globe continually grow, Non-alcoholic Steatohepatitis, or NASH, is rapidly becoming a serious health concern. NASH is estimated to affect 3 – 5% of the global population; well over two hundred million people worldwide1

Yet, despite its prevalence and severity, there are still no drug therapies approved for the treatment of NASH.

Register free for full access to